Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema
Allergy · 2026
DOI: 10.1111/all.70263 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Allergy, 2026. Verfasst von Perrine Gery und 25 weiteren Autor:innen. Beteiligte Einrichtung: Centre International de Recherche en Infectiologie, University of Lyon 1 and École Normale Supérieure de Lyon, Inserm U1111, Lyon, France. Hauptthemen laut MEDLINE: Eczema, Hand Dermatoses. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi US ISS, Acteria Fundation, Agence Nationale de la Recherche.
Abstract (Originalsprache)
Background
Chronic hand eczema (CHE) is a debilitating skin condition characterized by pain, itch, and chronic inflammation, with a complex multifactorial origin. Its diverse presentations, including overlapping traits of atopic dermatitis, contact dermatitis, and psoriasis, make diagnosis and treatment particularly challenging. The underlying immune mechanisms of CHE still need to be investigated.
Methods
Here we conducted a comprehensive molecular profiling of CHE patients, enrolled without prior selection on etiology and morphology, and performed a phase 2b randomized, multicenter, double‐blind, placebo‐controlled clinical trial comparing dupilumab to placebo over 16 weeks.
Results
We demonstrated that CHE patients may benefit from IL4Rα‐blockade, regardless of etiological factors or clinical presentation. Skin transcriptomic and serum profiles of CHE patients closely resemble those seen in both atopic dermatitis and psoriasis, with dysregulated genes affecting keratinocyte differentiation, leucocyte‐mediated immunity, cytokine signaling, and mixed type 1, 2, and 3 immunity. The clinical trial included 94 adults with moderate to severe CHE persisting for at least six months and resistant to potent topical corticosteroids. Compared to placebo control, 16‐week dupilumab treatment significantly improved clinical severity and quality of life of all CHE patients while largely restoring appropriate transcriptomic and proteomic programs related to skin barrier and immune homeostasis.
Conclusion
These findings confirmed the involvement of not only type 2 but also type 1 and type 3 immunity across all CHE patients, and demonstrate that IL‐4Rα blockade may offer effective therapeutic perspectives for this highly burdensome condition, independent of an atopic dermatitis background.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre International de Recherche en Infectiologie, University of Lyon 1 and École Normale Supérieure de Lyon, Inserm U1111, Lyon, France.
- Infinity (Institut Toulousain des Maladies Infectieuses et Inflammatoires), Immception Lab, Inserm U1291, Toulouse University, Toulouse, France.
- Department of Clinical Epidemiology and Public Health, Toulouse University Hospital, Toulouse, France.
- CERPOP, Inserm, University Toulouse III Paul Sabatier, Toulouse, France.
- Department of Dermatology, Saint-Eloi Hospital, Montpellier University, Montpellier, France.
- Department of Dermatology, Larrey Hospital, Toulouse University, Toulouse, France.
ORCID-Profile: Rüçhan Ekren, Hugo Rimet, Nadia Raison-Peyron, Lilian Basso, Cristina Bulai Livideanu, Marc Vocanson, Nicolas Gaudenzio, Marie Tauber
Förderung
- Sanofi US ISS
- Acteria Fundation
- Agence Nationale de la Recherche
- European Research Council
Zitieren
APA
Gery, P., Ekren, R., Bérard, E., Du-Thanh, A., Rimet, H., Jendoubi, F., Lenief, V., Raison-Peyron, N., Bouznad, A., Konstantinou, M. P., Rioual, J., Basso, L., Mouiren, J., Boussier, M., Milpied, B., Bulai Livideanu, C., Jaulent, L., Hacard, F., Lefevre, M. A., …, & French Atopic Dermatitis Network from de GREAT Research group (2026). Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema. Allergy. https://doi.org/10.1111/all.70263
Vancouver
Gery P, Ekren R, Bérard E, Du-Thanh A, Rimet H, Jendoubi F, et al. Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema. Allergy. 2026. doi:10.1111/all.70263
BibTeX
@article{Gery2026,
author = {Gery, Perrine and Ekren, Rüçhan and Bérard, Emilie and Du-Thanh, Aurélie and Rimet, Hugo and Jendoubi, Fatma and Lenief, Vanina and Raison-Peyron, Nadia and Bouznad, Amel and Konstantinou, Maria P and Rioual, Jonathan and Basso, Lilian and Mouiren, Juliette and Boussier, Manon and Milpied, Brigitte and Bulai Livideanu, Cristina and Jaulent, Louise and Hacard, Florence and Lefevre, Marine A and Nosbaum, Audrey and Seneschal, Julien and Vocanson, Marc and Paul, Carle and Gaudenzio, Nicolas and Tauber, Marie and French Atopic Dermatitis Network from de GREAT Research group, French Atopic Dermatitis Network from de GREAT Research group},
title = {Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema},
journal = {Allergy},
year = {2026},
doi = {10.1111/all.70263}
}
EUVIMED